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A B S T R A C T
Resiquimod (R848), a member of the imidazoquinoline family, is a Toll-like receptor 7/8 agonist with high
potency for cancer immunotherapy. However, tolerance induction and adverse eﬀects limit its development as a
drug. Encapsulation in a polymer matrix can circumvent these limitations, as shown in our formerly published
approach where R848 was loaded into polylactic acid (PLA)-based nanoparticles (NP). Although the results were
encouraging, low rates of encapsulation and rapid release of the drug were observed. In this study, we present a
new strategy using mixed NP from modiﬁed linear PLA in order to improve the encapsulation and modulate the
release proﬁle of R848. Modiﬁed PLA polymers were designed and synthesized by microwave-assisted ring
opening polymerization of D,L-lactide, using polyethylene glycol as initiator to increase the hydrophilic prop-
erties of the polymer or linear saturated aliphatic chains (C8 or C20) to increase the aﬃnity with hydrophobic
R848. NP were prepared by solvent evaporation method, leading to particles of 205–288 nm loaded with either
R848 or DiO as a tracking agent. The release proﬁle showed longer retention of R848 at both neutral and acidic
pH for NP from grafted polymers. Upon exposure to phagocytic immune cells, NP were actively taken up by the
cells and no impact on cell viability was observed, independently of the constitutive polymer. All R848-loaded
NP activated macrophages to secrete interleukin-6, demonstrating that the drug cargo was immunologically
active. Importantly, macrophage activation by NP-delivered R848 was slower than with free R848, in ac-
cordance with the in vitro release proﬁles. Thus, NP prepared from modiﬁed PLA polymers showed no signs of
toxicity to immune cells and eﬃciently delivered their immunoactive cargo in a delayed manner. This delivery
strategy may enhance the eﬃcacy and safety of small-molecule immunostimulants.
1. Introduction
Cancer immunotherapy is based on the reactivation of immunity
against tumor tissues. During the initiation of an anticancer immune
response, antigen-presenting cells (APC) take up tumor antigens within
the tumor tissue to carry them to the lymph nodes. There, the APCs
activate cytotoxic T cells, which migrate back to the tumor to kill the
cancer cells [1]. Importantly, the APCs must themselves ﬁrst be acti-
vated through their pattern-recognition receptors, in order to be fully
functional. The Toll-like receptors (TLRs) are one of the main families
of pattern-recognition receptors expressed by APCs, and their stimula-
tion by endogenous or exogenous ligands leads to the production of
proinﬂammatory cytokines [2]. Imidazoquinolines are a family of
small-molecule immune response modiﬁers that stimulate speciﬁcally
the TLRs 7 and 8 [3]. In this family, imiquimod and resiquimod (R848)
are two low molecular weight and poorly water-soluble highly potent
synthetic molecules with a very similar chemical structure. Imiquimod-
based creams are approved for the treatment of diﬀerent cutaneous
malignant neoplasms after topical application [4–6]. Resiquimod has
been described as a more potent inducer of cytokines in peripheral
blood mononuclear cells [7,8]. Imidazoquinolines have been tested for
the systemic treatment of non-skin cancers [9]. However, the outcome
of these studies were quite disappointing, partly due to a phenomenon
of TLR tolerance [10] and a poor bioavailability related to the poor
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water solubility of the molecules. Furthermore, adverse eﬀects such as
leukopenia have also been described [11,12].
The use of nanoparticles (NP) made of polylactic acid (PLA) or poly
(lactic-co-glycolic) acid (PLGA) to improve the biodistribution of hy-
drophobic active pharmaceutical ingredients (API) while reducing the
possible side eﬀects has been widely studied and proved eﬃcient
[13,14]. However, only a few publications, mainly published in the last
two years, deal with the use of these NP loaded with im-
munomodulators for the promotion of an eﬃcient in vivo immune re-
sponse [15–18]. We recently showed that NP made of methoxy-poly-
ethylene glycol PLA (mPEG-PLA) copolymers or a mixture of PLGA and
mPEG-PLA copolymers represented a promising and safe delivery
system to target resiquimod to lymph nodes [19]. We also showed that
we were able to change PLA-based NP release kinetics, by chemically
modifying the PLA polymers they are made with [20]. Among the main
outcomes of these studies, it appeared necessary to improve the release
kinetics of resiquimod with a better control of the burst eﬀect and a
prolongation of the release over time.
In his work dedicated to the synthesis and use of novel modiﬁed PLA
copolymers, Michael Möller demonstrated that adding a hydrophobic
pattern to the polymer backbone signiﬁcantly changed the properties of
the resulting polymeric micelles [21–24]. Indeed, starting from a
monohexyl-substituted or dihexyl-substituted D,L-lactide, the syntheses
of modiﬁed PLA polymers by ring opening polymerization (ROP) led to
polyesters in which half or all monomer units were functionalized by a
hexyl group. This change improved the drug loading capacity of the
resulting drug delivery system (DDS) and drastically slowed down the
release kinetics of various active ingredients.
In the present project, a deeper investigation of the impact of
modiﬁed PLA on the loading of resiquimod and its release kinetic
proﬁle is presented. For this purpose, mPEG2000, octanol or eicosanol
were grafted to the PLA backbone while synthesizing 40 kDa polymers
via microwave-assisted ROP of D,L lactide. We then prepared NP with
PLA and modiﬁed PLA and compared their loading capacities and in
vitro release kinetics. While hydrophilic mPEG2000 was selected to in-
crease the biodistribution of the NP suspension, the hydrophobic linear
aliphatic chains were selected to enhance the hydrophobic character-
istics of NP and therefore to improve encapsulation rate and extend the
drug release proﬁle. This study illustrates how the chemical modiﬁca-
tion of PLA can improve resiquimod loading in PLA-based NP. These NP
were investigated to compare their biological activity on cell uptake
and cytotoxicity as well as immune cell activation.
2. Material and methods
2.1. Materials for NP synthesis
D,L-lactide, stannous octoate (Sn(Oct)2), 1,8-diazabicyclo(5.4.0)
undec-7-ene (DBU), initiators (D,L-lactic acid, octanol, eicosanol and
methoxy-poly(ethylene glycol) 2000 (mPEG2000)), 3,3′Dioctadecyl-ox-
acarbocyanine perchlorate (DiO), polyvinyl alcohol (PVAL) (Mowiol
4–88, 26000 Da, 88% hydrolysis) and sucrose were purchased from
Sigma-Aldrich (St. Louis, MO, USA). Resiquimod (R848) was purchased
from Enzo Life Sciences. Chloroform (CHCl3), dichloromethane
(CH2Cl2), methanol (MeOH), hexane, tetrahydrofuran (THF) were
purchased from Sigma-Aldrich (St. Louis, MO, USA). Phosphate-buﬀer
saline (PBS) and fetal calf serum (FCS) were purchased from Gibco
(Thermo Fisher Scientiﬁc, Inc., Waltham, MA, USA).
All materials were used as received without any further puriﬁcation.
Water was ﬁltered through a Millipak 40 ﬁlter by a Millipore system.
2.2. Synthesis of PLA-based polymers
A solution of octanol or eicosanol (1 eq) as initiator, D,L-lactide
(278 eq), and Sn(Oct)2 as a catalyst (5 mol% relative to D,L-lactide) in
CHCl3 or a solution of lactic acid or mPEG2000 (1 eq) as initiator, D,L-
lactide (278 eq), and DBU as a catalyst (5mol% relative to D,L-lactide)
in CHCl3 was irradiated in a microwave reactor (Biotage® Initiator+,
Uppsala, Sweden) at 175 °C or at 125 °C for 5min under nitrogen at-
mosphere. The resulting mixture was poured into HCl 0.1 M and ex-
tracted with CH2Cl2, washed with brine and water. Hexane was then
added to the organic layer and the precipitate was centrifuged for 5min
at 3000g. After 3 cycles of dissolution of the pellet in a mixture of
CH2Cl2/MeOH (8:2), precipitation in hexane and centrifugation for
5min at 3000g, the resulting pellets were dried under reduced pressure
to give PLA, PLA-C8, PLA-C20 and PLA-mPEG2000 as white solids in
60%, 35%, 23% and 83% yield, respectively.
2.3. Characterization of PLA-based polymers
The chemical structure and molecular composition of PLA-based
polymers were determined by proton nuclear magnetic resonance (1H
NMR) spectroscopy in deuterated chloroform (CDCl3) on a Varian
Gemini 300MHz NMR spectrometer (Palo Alto, CA, USA).
2.4. Preparation of nanoparticles
NP were prepared by emulsion solvent evaporation method as re-
ported in Widmer et al. 2018 [19]. Brieﬂy, 150mg of polymers (the
diﬀerent ratios of PLA-based polymers are presented in Table 1) dis-
solved in 1ml dichloromethane were emulsiﬁed in 2ml of a 2.5% PVAL
solution (w/v) by ultrasonication (Branson Ultrasonics, Danbury, USA)
for 40 s and with an amplitude of 50% in an ice bath. The freshly
prepared emulsion was then added dropwise to 50ml of ultra-pure
water and stirred 1 h at 1450 rpm with an Ultra-Turrax Eurostar digital
Euros ST D (IKA-Werke GmbH & Co., Staufen, Germany) in an ice bath.
The stirring speed was then reduced to 600 rpm and the solution was
stirred for 2 h at room temperature to allow solvent evaporation. 3
cycles of washing and centrifugation using an Avanti 30 Centrifuge
(Beckman, USA) equipped with a F1010 Fixed-Angle Rotor (Beckman,
USA), each time for 20min at 34000g, were ﬁnally necessary to obtain
10ml of a pure suspension of NP. The latter was then divided in ﬁve
fractions of 2ml in which 1ml of a 15% w/w sucrose aqueous solution
was added as cryoprotectant. The samples were freeze dried using a
Christ Alpha 2–4 LD plus freeze dryer (Christ, Osterode am Harz, Ger-
many).
For loaded NP, either R848 (5mg) or DiO (22.5 μg) were solubilized
in dichloromethane and added to the polymer solution.
For R848-loaded NP, one fraction of 2ml of pure suspension of NP
was freeze-dried without additional sucrose in order to determine the
drug loading.
Burst-free samples of R848-loaded NP were prepared for speciﬁc
biological experiments to study the eﬀect of the encapsulated fraction
of R848. The R848-loaded NP were suspended in PBS supplemented
with 10% (v/v) FCS for 40min at 37 °C under a gentle shaking
(80 rpm). One cycle of washing and centrifugation (20min at 34000g),
was applied to obtain 2ml of a suspension of burst-free NP in which
1ml of a 15% w/w sucrose aqueous solution was added before freeze-
Table 1
Composition of the diﬀerent batches of PLA-based NP.
NP name Polymer composition of NP (proportion w/w) Loading
PLA-PEG2000 PLA PLA-C8 PLA-C20
u-NP 1/3 2/3 / / /
u-NP-C8 1/3 / 2/3 / /
u-NP-C20 1/3 / / 2/3 /
DiO-NP 1/3 2/3 / / DiO
DiO-NP-C8 1/3 / 2/3 / DiO
R848-NP 1/3 2/3 / / R848
R848-NP-C8 1/3 / 2/3 / R848
R848-NP-C20 1/3 / / 2/3 R848
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drying.
2.5. Nanoparticle characterization
2.5.1. Dynamic light scattering
NP size were determined before lyophilization by dynamic light
scattering with a Zetasizer 3000 (Malvern Instruments, Ltd., U.K.) after
dilution of nanoparticle suspensions in Milli-Q ﬁltered water according
to the supplier’s recommendations: ca. 0.1 mg/ml to get a slightly
opalescent suspension.
2.5.2. Scanning electron microscopy
NP morphology was determined by scanning electron microscopy
(SEM) using a JSM-7001FA microscope (JEOL, Tokyo, Japan). A drop
of aqueous suspension of NP was placed onto a carbon-coated stub,
dried under vacuum and covered with a 15–20 nm layer of gold. The
stubs were observed at an emission of 5.0 kV and a working distance of
9.3–12.0 nm. Pictures were taken for each sample at a magniﬁcation of
20000.
2.5.3. Drug loading
Samples of freeze-dried R848-loaded NP and freeze-dried burst-free
R848-loaded NP (3mg) were dissolved in HPLC grade DMSO (300 μl)
and the loaded amount of R848 was quantiﬁed by a U-HPLC separation
performed by a Thermo Scientiﬁc Accela LC system equipped with a
Thermo Scientiﬁc Accela PDA (Thermo Fischer Scientiﬁc, Waltham,
USA). The column used was a C18 Hypersil Gold (50x2.1 mm, 1.9 μm
particle size, 175 Å pore size; Thermo Fischer Scientiﬁc, Waltham,
USA). The chromatographic separation was carried out with a linear
gradient mode starting from 2% acetonitrile and 98% of water con-
taining 0.1% of formic acid (1.8–4min) to 98% of acetonitrile con-
taining 0.1% of formic acid (for 2min) and 2% of water with a ﬂow rate
of 400 μl/min. R848 was detected at 320 nm wavelength. The injection
volume was 10 μl. The peak of R848 was well separated in the chro-
matographic conditions established. The quantity of R848 was calcu-
lated by interpolation from the calibration curves. The calibration
curves were linear within the 1.5–150 μg/ml range for R848, with a
correlation coeﬃcient (R2) greater than 0.99. The method was adapted
from Cruz et al. [25].
2.6. In vitro release kinetics
A suspension of 30mg of freeze-dried R848-loaded NP in 10ml PBS
supplemented with 10% (v/v) FCS was split into vials containing 200 μl
of the suspension and stirred at 80 rpm and 37 °C for diﬀerent times (t0,
15 min, 30min, 45min, 1 h, 2 h, 3 h, 6 h, 12 h, 24 h, 48 h, 72 h, and
168 h), each in triplicate. At each time point, the suspensions were
centrifuged at 16000g for 5min (Avanti 30 centrifuge, Beckman, IN,
USA) and the ﬂuorescence of resiquimod in the supernatant was
quantiﬁed by a U-HPLC separation with the same equipment as de-
scribed above. The chromatographic separation was carried out with a
linear gradient mode starting from 90% of water containing 0.1% of
formic acid (1–4.5min) to 98% of acetonitrile containing 0.1% of
formic acid (4.5–6min) with a ﬂow rate of 400 μl/min. R848 was de-
tected at 320 nm wavelength. The injection volume was 10 μl.
The same protocol was followed on suspension of freeze-dried burst-
free R848-loaded NP either in PBS supplemented with 10% (v/v) FCS or
in acetate buﬀer pH 4.5 for diﬀerent times (t0, 30min, 1 h, 2 h, 4 h, 6 h,
9 h, 12 h, 24 h, 48 h, 72 h, and 168 h).
2.7. Cell line
The murine macrophage cell line J774.1 (ATCC) was cultured in
complete medium consisting of high glucose (4.5 g/l) DMEM (Biowest),
10% FCS (Biological industries), 2 mmol/ml L-glutamine (PAA), 1 mM
sodium pyruvate (PAA), 1 IU/ml penicillin (PAA), and 100 μg/ml
streptomycin (PAA). For experiments, cells were seeded in a ﬂat-bottom
96-well plate at a concentration of 5× 104 cell/ml (100 μl per well)
and cultured overnight at 37 °C in 5% CO2 before exposure to NP.
2.8. NP dilution
The NP concentrations selected for biological assays were based on
R848 encapsulation values. Unloaded NP were used at the same con-
centration as the corresponding R848-loaded NP. Lyophilized NP were
suspended in complete medium at 2 times the R848 working con-
centration (R848 working concentration: 0.1 μg/ml) and added to the
cells in a 1:1 ratio.
2.9. NP uptake into cells
J774 cells were exposed for 3 h to DiO-labeled NP at 4 °C or 37 °C.
Next, cells were washed in PBS and stained with Zombie Violet
(Biolegend) to exclude dead cells. Live cells were analyzed for NP up-
take and expressed as the percentage of DiO-positive cells.
Splenocytes were harvested from C57BL/6 mice (Janvier Labs) in
accordance with Swiss regulations for animal experimentation. Brieﬂy,
spleens were cut in pieces, passed through a 70 μm strainer, and washed
with PBS. Red blood cell lysis (BD Pharm Lyse, BD) was performed
according to the manufacturer's instructions. Cells were resuspended in
complete medium: RPMI1640 (PAA), 2 mol/l L-glutamine (PAA), 1 IU/
ml penicillin (PAA), 100 μg/ml streptomycin (PAA), 0.1mM non-es-
sential amino acid (PAA), 1 mM sodium pyruvate (Life Technologies)
and 25 μM betamercapto-ethanol (Life Technologies). Splenocytes
(2×106 cells/ml in a 12-well plate) were incubated for 2 h with DiO-
NP, harvested and washed twice with PBS. Cells were then incubated
with FcX Block CD16/32 for 15min prior to the addition of the fol-
lowing antibodies: CD11b (APC, clone M1/70), CD3 (Paciﬁc Blue, clone
17A2), CD19 (APC-Cy7, 6D5) and CD11c (PE, clone N418), all from
Biolegend. Immune cell subtypes were deﬁned as follows: T lympho-
cytes (CD3+), B lymphocytes Monocytes/macrophages (CD11b+,
CD11c-), dendritic cells (CD11b+, CD11c+). The diﬀerent cell types
were analyzed for NP uptake, expressed as the percentage of DiO-po-
sitive cells within that cell subtype.
2.10. Viability assay
J774 cells (5× 104 cells in 100 μl/well) were exposed to NP for
24 h. Staurosporine (0.1 μM) was used as a positive control for cell
death. Cells were stained with Annexin V in Annexin V buﬀer
(Biolegend) to determine apoptotic cells. Zombie Violet staining
(Biolegend) was used (diluted 1:1000 in PBS) as staining for dead cells.
Flow cytometry analysis were performed by MACSquant analyzer 10
(Miltenyi Biotec).
2.11. Immune cell activation
J774 cells (5× 104 cells in 100 μl/well) were exposed to NP for
diﬀerent times. The working concentration of all R848-NP conditions
was 0.1 μg/ml. Free R848 was used as positive control (0.1 μg/ml).
After incubation, supernatants were harvested and analyzed by ELISA
MAX kit (Biolegend) for interleukin-6 (IL-6) according to the manu-
facturer’s protocol. Absorbance was read by an Inﬁnite 200 PRO plate
reader (TECAN).
To assess the release of bioactive R848 from the NP, NP were in-
cubated in complete medium (37 °C) for 1 h, 3 h, 6 h or 24 h without
cells. NP were then centrifuged for 30min at 12000g and supernatant
was collected. NP supernatant was then added to J774 cells as a re-
placement of culture media. After 24 h, cell supernatant was collected
and analyzed by ELISA for IL-6.
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3. Results and discussion
3.1. Synthesis of PLA-based polymers
In this study, one non-modiﬁed “bare” PLA, named PLA thereafter,
and three linear modiﬁed PLA were designed and synthesized via mi-
crowave-assisted ROP of D,L-lactide using diﬀerent hydroxyl group
bearing initiators (Fig. 1A). The use of microwave-assisted chemistry
was preferred to classical thermal heating, due to its excellent tem-
perature control, thereby preventing thermal decomposition or side
reactions and leading to homogeneous batches of polymers [26]. On the
one hand, PLA synthesis was initiated by D,L-lactic acid. On the other
hand, modiﬁed PLA syntheses were either initiated by octanol or ei-
cosanol, C8 and C20 linear saturated aliphatic alcohol, respectively, to
graft hydrophobic properties to the polyester backbone, or mPEG2000 to
graft hydrophilic properties, to obtain PLA-C8, PLA-C20 and PLA-
mPEG2000, respectively (Fig. 1B). PLA was used as a reference. In order
to be consistent with our previous work, and to allow a comparative
study, we set the molecular weight of the four polymers at 40 kDa by
using an accurate initiator to monomer ratio: 1 equivalent of initiator
and 278 equivalents of D,L-lactide. Purity and molecular weight of the
synthesized polymers were conﬁrm by 1H NMR spectroscopy by ob-
serving the absence of peaks corresponding to D,L-lactide and by in-
tegrating multiplets from PLA (5.17 ppm and 1.57 ppm) and singlet
from mPEG (3.64 ppm), eicosanol or octanol (1.25 ppm), respectively
(Supplementary Fig. S1). The analyses showed in all cases a total con-
version of monomers into polymers and a ﬁnal molecular weight, given
as weight average, close to the predicted 40 kDa. All modiﬁed PLA were
obtained as white solids with yields ranging from 23 to 35% when
stannous octoate was used as catalyst and from 60 to 83% with DBU.
Among his research projects, Michael Möller focused on tuning the
hydrophilic/lipophilic balance of PLA by developing mPEG-poly
(monohexyl-substituted lactides) (mPEG-mHexPLA) or mPEG-poly(di-
hexyl-substituted lactides) (mPEG-diHexPLA). In contrast to our ap-
proach, the hydrophobicity was not provided by the initiator but by the
substituted D,L-lactides. By varying the number of hexyl groups along
the PLA chain, the increased loading abilities of micelles made from
mPEG-mHexPLA or mPEG-diHexPLA have been clearly demonstrated
with diﬀerent hydrophobic compounds [21–24,27].
As we focused on the delivery of resiquimod for systemic adminis-
tration, the main objective of this study was to obtain an adapted drug
release. We demonstrated recently the interest of encapsulating R848
into derivatives of PLA-based NP to trigger an immune response [19].
However, these particles exhibited a fast burst release. Therefore, we
decided to increase the hydrophobicity of the polymer to favor R848
retention while optimizing its release. Our aim was to prevent release of
the cargo during the transport of the NP to the lymph nodes, in order to
obtain only a local immune activation in the targeted lymphoid organs
rather than a systemic activation. Such a systemic activation by small-
molecule TLR7 agonists has been shown to be toxic [28]. Thus our
linear modiﬁed PLA polymers, taking the example of a 40 kDa PLA,
were grafted with only one C8 or C20 aliphatic chain to the polyester
backbone instead of 139 and 278 C6 aliphatic side chains in case of
mPEG-mHexPLA and mPEG-diHexPLA, respectively.
3.2. Preparation and characterization of PLA-based nanoparticles
Batches of NP made of PLA, PLA-C8 or PLA-C20 (2/3 w/w) and
PLA-mPEG2000 (1/3 w/w) were synthesized by a solvent evaporation
method. These NP were either loaded with R848 as the active molecule
(R848-NP and R848-NP-C8), loaded with DiO as a ﬂuorescent probe
(DiO-NP and DiO-NP-C8) or unloaded (u-NP, u-NP-C8 and u-NP-C20)
(Table 2). Dynamic light scattering (DLS) analyses showed a mono-
modal distribution of size for all samples ranging from 205 to 288 nm
with a general polydispersity index (PDI) lower than 0.18. Scanning
electron microscopy (SEM) (Fig. 2) conﬁrmed the spherical and
homogeneous shape of NP as well as larger sizes in case of R848-loaded
NP. Regarding the loading properties of the diﬀerent NP, Table 2 shows
that R848-NP was able to load ﬁve times more resiquimod than R848-
NP-C8 and R848-NP-C20, although PLA-C8 or PLA-C20 polymers were
speciﬁcally designed to improve hydrophobic interactions with the API
thus resulting in an increased ability to load the API inside the
Fig. 1. General scheme of microwave-assisted ROP of D,L-lactide initiated by hydroxyl group bearing compounds (A) and chemical structure of the PLA-based
polymers synthesized (B).
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corresponding NP. Steric hindrance might explain the lower loading
eﬃciency due to the generation of a structural disorder in the ﬁnal NP
matrix. However, in case of burst-free R848-loaded NP the ability of NP
made of PLA to load more resiquimod than NP made of modiﬁed PLA
was still observed but this time with only a factor 3 giving a favorable
result on the ability of modiﬁed PLA-based NP to better retain the API.
We also did not observe signiﬁcant diﬀerence between R848-loaded NP
made of C8-modiﬁed polymers or C20-modiﬁed polymers.
3.3. In vitro release kinetics
To evaluate the inﬂuence of PLA structural changes on drug release,
we investigated the in vitro release kinetics of the three types of R848-
loaded NP (Fig. 3). This assay was ﬁrst carried out on samples of freeze-
dried R848-loaded NP in PBS pH 7.4 supplemented with 10% v/v FCS
at 37 °C, over a period of seven days and maintaining sink conditions.
This aqueous medium was used to mimic the biological environment
that would be encountered during the diﬀusion towards the target cells.
A 100% release of R848 corresponds to the maximum amount of drug
contained in NP and determined by the drug loading assays.
Fig. 3A shows that the burst release, equivalent to the rapid deso-
rption of drug from the NP surface, was similar in all cases with more
than 15% of resiquimod released in the ﬁrst 15min. This observation
might be the consequence of a similar external structure of the R848-
loaded NP. Indeed, all NP types are composed of 1/3 w/w of PLA-
mPEG2000 copolymer whose hydrophilic moieties are mainly located in
the outer shell of the resulting NP. The burst release phase was then
followed by the controlled release phase which corresponds to the re-
lease of the drug due to diﬀusion through the DDS matrix or degrada-
tion of the DDS matrix and depends on the nature of the interactions
Table 2
Characterization of the NP batches.
NP Mean size in
intensity [nm]
PDI μg R848/mg NP (entrapment
eﬃciency [%])
R848-loaded
NP
Burst-free R848-
loaded NP
u-NP 217 0.14
u-NP-C8 230 0.05
u-NP-C20 257 0.05
DiO-NP 205 0.18
DiO-NP-C8 213 0.07
R848-NP 282 0.13 12.03 (36) 3.12 (9)
R848-NP-C8 288 0.10 2.64 (8) 1.02 (3)
R848-NP-C20 282 0.09 2.66 (8) 1.08 (3)
Fig. 2. Scanning electron microscopy images of unloaded (u-NP-C20 (A), u-NP-C8 (B) and u-NP (C)) and R848-loaded NP (R848-NP-C20 (D), R848-NP-C8 (E) and
R848-NP (F)) (scale bar= 1 μm).
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between the API and the DDS [29]. In the case of R848-NP, this dif-
fusion-dependent release reached a cumulative amount of resiquimod
of 100% after 48 h followed by a plateau. For R848-NP-C8 and R848-
NP-C20, 62% and 52% of resiquimod were released after 48 h. This was
followed by another phase corresponding to a slower release of the API
to ﬁnally reach a cumulative amount of resiquimod of 88% and 65% for
R848-NP-C8 and R848-NP-C20, respectively, from 48 h to 168 h. The
trend observed in this kinetic study suggests that R848-NP-C8 and
R848-NP-C20 retain resiquimod better than R848-NP, which is con-
sistent with our expectations. No diﬀerences were observed between
R848-NP-C8 and R848-NP-C20.
A burst eﬀect was observed with the ﬁrst set of samples. Burst-free
R848-loaded NP were therefore produced by suspending R848-loaded
NP in PBS buﬀer at 37 °C for 40min under gentle stirring to eliminate
the fraction of R848 which was weakly incorporated in the outer shell
of NP. In vitro release kinetics were then carried out on these samples
either in PBS pH 7.4 supplemented with 10% v/v FCS or in acetate
buﬀer pH 4.5. Acetate buﬀer was selected to mimic the acidic milieu of
the endosome of APCs where the TLR7, target of R848, is located [30].
The burst eﬀect considerably decreased when PBS/FCS was used
(Fig. 3B) as less than 15% of resiquimod were released after 1 h. No
release was observed with burst-free R848-NP-C8 and burst-free R848-
NP-C20 over the same period. Then, a rapid release phase was observed
over a period of 48 h for burst-free R848-NP to reach a cumulative
amount of resiquimod of 51%. This rapid release was observed after
only 12 h with burst-free R848-NP-C8 and burst-free R848-NP-C20, to
reach a cumulative amount of resiquimod of 12% and 16%, respec-
tively. Finally, a slower release phase was observed to reach 59%, 27%
and 51% of resiquimod released from burst-free R848-NP, burst-free
R848-NP-C8 and burst-free R848-NP-C20, respectively, from 24 h to
Fig. 3. In vitro release proﬁles of R848 from R848-loaded NP in PBS pH 7.4 supplemented with 10% v/v FCS (A), and from burst-free R848-loaded NP in PBS pH 7.4
supplemented with 10% v/v FCS (B) and in acetate buﬀer pH 4.5 (C), over a period of 168 h at 37 °C. Each value represents mean ± SD, n=3.
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168 h. In acetate buﬀer (Fig. 3C), we also observed a lower burst eﬀect
as less than 10% of resiquimod were released after 1 h in all cases.
Then, cumulative amounts of resiquimod of 74%, 12% and 38% after
24 h were observed with burst-free R848-NP, burst-free R848-NP-C8
and burst-free R848-NP-C20, respectively. It was followed by a slower
release of API to ﬁnally reach a cumulative amount of resiquimod of
88%, 31% and 53% for burst-free R848-NP, burst-free R848-NP-C8 and
burst-free R848-NP-C20, respectively, from 24 h to 168 h.
Both in vitro release proﬁles of R848 from burst-free R848-loaded
NP in PBS pH 7.4 supplemented with 10% v/v FCS and in acetate buﬀer
pH 4.5 showed a better retention of the API by modiﬁed PLA-based NP.
This observation was even more evident in acetate buﬀer as more than
50% of resiquimod was released after 6 h with PLA-based NP vs less
than 20% with modiﬁed PLA-based NP, thereby proving the interest of
adding hydrophobic chains on the PLA backbone.
3.4. Uptake of PLA-NP by immune cells
We then examined how the PLA-based NP interact with cells of the
immune system. Macrophages and dendritic cells are immune cells
specialized in the uptake and processing of particulate material. To
assess whether the PLA-based NP were taken up by these cells, we ex-
posed a macrophage cell line, J774, to NP or NP-C8 labeled with the
ﬂuorescent marker DiO at 4 °C or 37 °C. Cells were then analyzed by
ﬂow cytometry and the percentage of DiO-positive cells was de-
termined. Both types of NP were eﬃciently taken up by the macro-
phages at 37 °C, with approximately 70% of cells labeled with DiO after
3 h independently of the polymer. Low temperature reduces en-
docytosis activity [31], and the incubation at 4 °C consequently showed
a lower proportion of DIO-positive cells, at around 50% for DiO-NP and
20% for DiO-NP-C8 (Fig. 4A and B). It is possible that in the absence of
active internalization processes at low temperatures, the DiO-labeled
particles were not internalized by the cells at 4 °C but rather adhered to
the cell surface.
To examine whether the PLA-based NP were also taken up by pri-
mary immune cells rather than a cell line, freshly isolated mouse
splenocytes were exposed to ﬂuorescently labeled NP for 2 h at 37 °C.
Mouse splenocytes are composed of many diﬀerent immune cells types,
which can be easily distinguished by ﬂow cytometry. We observed that
DiO-NP and DiO-NP-C8 were mainly taken up by macrophages after
this short incubation time. In contrast, T and B lymphocytes as well as
dendritic cells showed few DiO-positive cells (Fig. 4C). Thus, highly
phagocytic cells such as macrophages actively take up diﬀerent PLA NP.
3.5. Impact of PLA-NP on macrophage viability
In view of a future biomedical application of NP as a drug-loaded
carrier, it is essential to determine whether the NP show any cytotoxic
activity on immune cells. We exposed J774 macrophages to diﬀerent
types of NP loaded or not with R848 or to free R848 for 24 h and
measured cell viability by ﬂow cytometry. The NP concentration was
selected to deliver a pharmacologically active concentration of R848
(0.1 μg/ml). Staurosporine was used as positive control. Importantly,
NP had no signiﬁcant impact on cell viability in this experimental
setting, independently of the presence of their drug cargo (Fig. 5).
These results demonstrate that the PLA-NP do not impair the viability of
immune cells even at NP concentrations of at least 8 μg/ml.
3.6. Impact of PLA-NP on macrophage function
R848 is an immune-activating drug that binds to the Toll-like re-
ceptor 7 in the endosome of dendritic cells and macrophages. TLR7
activation leads to the production and secretion of pro-inﬂammatory
cytokines, such as interleukin-6 (IL-6) [32]. To determine whether the
R848 cargo of the NP could lead to immune activation, we measured
the secretion of IL-6 into the supernatant by J774 macrophages exposed
to diﬀerent types of PLA NP loaded with R848. We show that all R848-
loaded NP induced production of IL-6 by the macrophages after 24 h in
culture, and that the level of cytokines released was similar to the level
induced by free R848 (Fig. 6). Only slight diﬀerences were seen in the
levels of IL-6 released by exposure to R848-loaded NP with diﬀerent
chemical modiﬁcations of PLA. Importantly, NP without R848 cargo (u-
NP-C8, u-NP-C20) did not induce any IL-6 release, indicating that the
NP material alone does not have an immunostimulatory eﬀect. We
obtained similar ﬁndings for TNFα (Supplementary Fig. S2). We did not
detect secretion of IL-1β after exposure of J774 cells to either R848-
loaded or unloaded NP (data not shown).
Since we had shown that the release of R848 diﬀers between the
diﬀerent types of PLA-NP at early time points (Fig. 3), we examined the
impact of exposure of J774 macrophages to R848-loaded NP for shorter
incubation times. We found that R848-NP, R848-NP-C8 and R848-NP-
C20 all led to lower production of IL-6 by macrophages at 6 and 8 h
incubation, compared to the same amount of free R848 (Fig. 7A). The
diﬀerence was no longer detected after 12 h incubation. This is in line
with the data presented in Fig. 3 showing a controlled release of R848
by the NP.
To investigate how the diﬀerent release kinetics of R848 from the
NP aﬀect cell stimulation over time, we incubated burst-free NP in cell
culture medium at 37 °C for 1 to 24 h, collected the NP supernatant and
exposed J774 macrophages to the supernatant for 24 h. We then again
measured IL-6 production by macrophages. Supernatants harvested
after a 1-h incubation with all types of NP did not lead to IL-6 pro-
duction, supporting that R848 had not yet been released from the NP
(Fig. 7B). Supernatants harvested after a 3-h incubation of burst-free
Fig. 4. NP are eﬀectively taken up by antigen-presenting cells. Representative histogram (MFI) (A) and percentage of DiO-positive cells (B) after J774 macrophages
were incubated with DiO-labeled NP for 3 h at 4 °C or 37 °C and assessed by ﬂow cytometry. Freshly isolated mouse splenocytes were incubated with DiO-labeled NP
at 37 °C for 2 h (C). Each bar represents mean ± SD, n= 3. Data are representative of two separate experiments.
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R848-NP and burst-free R848-NP-C8 induced similar levels of IL-6,
whereas supernatants from burst-free NP-R848-C20 did not induce IL-6
production at this time point. This suggests that R848 had not been
released from the NP burst-free NP-R848-C20 after 3 h. No diﬀerence
was seen between the diﬀerent supernatants harvested after 6 h. In-
terestingly, the IL-6 production was higher for cells exposed to the su-
pernatant of burst-free NP-R848-C20 harvested after 24 h, compared to
supernatants from the other NP types. Overall, R848-loaded NP showed
delayed activation of the cells in the ﬁrst 8 h of incubation, compared to
free R848.
4. Conclusion
In this study, one bare PLA and three linear modiﬁed PLA (PLA-
mPEG2000, PLA-C8 and PLA-C20) were successfully synthesized using
microwave-assisted ROP of D,L-lactide. While PLA-mPEG2000 was syn-
thesized to improve the biodistribution of the resulting NP, PLA-C8 and
PLA-C20 were used to increase the aﬃnity with poorly water-soluble
R848. NP were then prepared by mixing PLA-mPEG2000 (1/3 w/w)
and PLA, PLA-C8 or PLA-C20 (2/3 w/w). Despite the changes made
since our previous work [20], encapsulation eﬃciency of resiquimod
remained low. Importantly, the use of PLA-C8 and PLA-C20 delayed the
release of R848, especially in acidic conditions. Burst issues observed
with R848-loaded NP were solved by preparing burst-free NP. Studies
with phagocytic immune cells demonstrated that the addition of ali-
phatic chains to the PLA backbone did not impair cellular uptake and
safety of the NP on macrophages. Moreover, all drug-loaded NP eﬃ-
ciently stimulated macrophages with a time lag in agreement with the
matrix eﬀect on drug release, showing the R848 cargo retained its
Fig. 5. PLA-NP do not impair macrophage viability. J774 cells were exposed for 24 h to diﬀerent NP formulations (R848 concentration: 0.1 μg/ml for free R848 and
all R848-loaded NP conditions). Representative ﬂow cytometry dot plots (A) and percentage of live cells (B). Each bar represents mean ± SD, n= 3. Data are
representative of three separate experiments. Stauro: staurosporine.
Fig. 6. R848-loaded PLA-NP activate cytokine release in macrophages. The
release of IL-6 from J774 cells was assessed after incubation for 24 h with un-
loaded or R848-loaded NP (R848 concentration: 0.1 μg/ml for free R848 and all
R848-loaded NP conditions). Each bar represents mean ± SD, n= 4. Data
show one representative experiment out of four. n.d.: not detected.
Fig. 7. R848-loaded NP activate macrophages more slowly than the free drug. IL-6 cytokine release after J774 cells exposure to R848-loaded NP or free R848 at
diﬀerent time points (A). IL-6 secretion by J774 cells after 24 h exposure to NP supernatant collected at diﬀerent time points (1–24 h) (B). Each bar represents
mean ± SD, n= 4. Data are representative of at least 2 separate experiments.
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immunostimulatory function. In future studies, release proﬁles could
further be optimized by using intrinsic properties of PLA and so by
adapting its molecular weight or the size of the resulting NP. Thus,
modiﬁcation of PLA polymers in NP preparation allows to control the
release kinetics for a small molecule immune response modiﬁer. A
stepwise and individualized optimization is necessary to obtain selected
release characteristics.
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